BASEL (dpa-AFX) - Ligand Pharmaceuticals Inc. (LGND) said it has entered
into global license and supply agreements with Novartis AG (NVS) for the
development and commercialization of a Captisol-enabled oral liquid formulation
In a letter to the U.S. Senate Special Committee on Aging, the founder and president of the Lantern Foundation urged Senate members to investigate a number of alleged offenses by Ligand Pharmaceuticals Inc. (NASDAQ: LGND).
"After several years...
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.
You may also be interested in articles related to Ligand Pharmaceuticals (LGND):